ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.33 · Revenue $124600.00 · 4 analysts
Est. EPS $-0.33 · Revenue $453400.00 · 4 analysts
Est. EPS $-0.66 · Revenue $507143.00 · 3 analysts
Est. EPS $-0.14 · Revenue $200000.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $893000 | +1075.0% | -33.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-69.0M | -12.7% | -25.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | 0.0% | +118.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -18477.8% | +92.4% | -62.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -7725.2% | +90.4% | -89.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-135.3M | +13.2% | +2.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -15152.6% | +92.6% | -46.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -0.4% | -22.7% | -7.9% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 9.13x | -16.5% | -7.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $335.6M | -23.9% | -14.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.52 vs -0.58 | +9.6% | -0.15 vs -0.14 | -7.1% |
| Revenue Surprise | $893000 vs $543429 | +64.3% | $150000 vs $186250 | -19.5% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Pereira Brian JG | director | Class A Common Stock | D | 27,052 | $1.42 |
| Aug 19, 2026 | Pereira Brian JG | director | Class A Common Stock | D | 222,949 | $1.44 |
| Aug 19, 2026 | Pereira Brian JG | director | Class A Common Stock | D | 27,051 | $1.44 |
| Aug 18, 2026 | Pereira Brian JG | director | Class A Common Stock | D | 229,338 | $1.37 |
| Aug 18, 2026 | Pereira Brian JG | director | Class A Common Stock | D | 27,826 | $1.37 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Bruce Culleton | Chief Executive Officer & Director | USD 1,181,281 | — | 1969 | Active |
Todd C. Girolamo | Chief Legal Officer & Secretary | USD 725,102 | Male | 1965 | Active |
James Coulston | Chief Financial Officer | USD 724,872 | Male | 1977 | Active |
Ulrich Ernst | EVice President of Science and Technology | USD 622,743 | — | 1962 | Active |
Gregory Madison | Chief Commercial Officer | — | Male | 1967 | Active |
Kenneth Locke | Chief Technical Officer | — | Male | — | Active |
Darin J. Weber | Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access | — | — | 1968 | Active |
Carla Poulson | Chief People Officer | — | Female | — | Active |
Emily Butler | Senior Vice President of Biometric | — | — | — | Active |
Joseph Stavas | SVP of Clinical Affairs | — | — | — | Active |
Richard Williams | Chief Information Officer | — | Male | — | Active |
ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK's cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising 'going concern' doubts.
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel
